Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

REALM THERAPEUTICS PLC (PURI)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 05/18 05:35:00 pm
39 GBp   --.--%
05/02REALM THERAPEUT : Final Results
PU
05/02REALM THERAPEUT : Realm Files Registration for Nasdaq Listing of ADS
PU
04/26REALM THERAPEUT : Notice of Results
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

PuriCore plc : PuriCore Raises $3.5 Million

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2012 | 09:11pm CEST
PuriCore plc ("PuriCore" or the "Company" or the "Group") PuriCore Raises $3.5 Million MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 3 January 2012 - PuriCore (LSE: PURI), the water- based clean technology company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, announces that it closed on a new $3.5 million debt facility with Republic Bank on 29 December 2011. The debt will be utilized to finance the working capital requirements associated with Sterilox Fresh and FloraFresh System installations in H1 2012. The facility is structured as a promissory note with an imputed interest rate of 4%. Enquiries:

FTI Consulting Susan Quigley Ben Brewerton

+44 (0) 20 7831 3113

About PuriCore

PuriCoreplc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. PuriCore's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.
To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

1

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REALM THERAPEUTICS PLC
05/02REALM THERAPEUTICS : Final Results
PU
05/02REALM THERAPEUTICS : Realm Files Registration for Nasdaq Listing of ADS
PU
04/26REALM THERAPEUTICS : Notice of Results
PU
03/13REALM THERAPEUTICS : Provides Clinical Update, including Results from a Phase 2 ..
AQ
02/20REALM THERAPEUTICS : Presentation at RBC Healthcare Conference
PU
02/16REALM THERAPEUTICS : Block listing Interim Review
PU
02/15REALM THERAPEUTICS : Clinical and Business Update
PU
01/02REALM THERAPEUTICS : Presents at 5th Annual Dermatology Summit
PU
2017REALM THERAPEUTICS : Director/PDMR Shareholding
PU
2017REALM THERAPEUTICS : First Patient Dosed in Phase 2 Study of PR013
PU
More news
Financials ( GBP)
Sales 2018 0,76 M
EBIT 2018 -
Net income 2018 -
Finance 2018 25,3 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 26,6x
EV / Sales 2019 52,7x
Capitalization 45,5 M
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Technical analysis trends REALM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Mark Sampson Vice President-Research & Development
Christian Peters Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC5.41%61
CELLTRION, INC.--.--%31 351
IQVIA HOLDINGS INC3.81%20 375
LONZA GROUP1.41%19 687
INCYTE CORPORATION-29.64%14 126
NEKTAR THERAPEUTICS42.83%13 568